Use of aminothiazole derivative in treatment of immune inflammation

A method for inhibiting activity of NLRP3, Caspase-1, Caspase-11, and Gasdermin D in cells derived from a human or animal, comprising:

• administering an effective amount of aminothiazole derivative to the cells;
• the aminothiazole derivative has the following formula:
• wherein, R1 is phenyl group or substituted aromatic group;
• R2 is benzyl, substituted benzyl, phenyl, or substituted phenyl;
• n=0, 1, 2.

An external preparation for treatment of superficial chronic inflammation, superficial chronic inflammation occurs on the surface of skin or mucosa and involves a process of pyroptosis, the ointment comprises the following components:

• Oil phase:
• liquid paraffin, stearic acid, white vaseline, octadecyl alcohol;
• Aqueous phase:
• hydroxyphenylate, sodium dodecyl sulfonate, triethanolamine, water, VE;
• Essence phase:
• glycerin, essence, azone;
• matrix:
• stearic acid, lanolin, VE, and octadecyl alcohol.
• Drug phase:
• aminothiazole derivative which has the following formula:
• wherein, R1 is phenyl group or substituted aromatic group;
• R2 is benzyl, substituted benzyl, phenyl, or substituted phenyl;
• n=0, 1, 2.

A method for treating depression, alzheimer's disease, obesity, fatty liver, burn injury, skin wound, rhinitis, psoriasis and dry eye syndrome, comprising:

• administering an effective amount of aminothiazole derivative to cells derived from a human or animal;
• the aminothiazole derivative has the following formula:
• wherein, R1 is phenyl group or substituted aromatic group;
• R2 is benzyl, substituted benzyl, phenyl, or substituted phenyl;
• n=0, 1, 2.